本文選題：腸道微生態(tài) + 腸易激綜合征�。� 參考：《中國(guó)實(shí)用兒科雜志》2017年02期

【摘要】：腸易激綜合征(IBS)是兒童慢性腹痛的常見(jiàn)原因,發(fā)病率高,長(zhǎng)期可嚴(yán)重影響生活質(zhì)量。IBS確切發(fā)病機(jī)制不明,近年發(fā)現(xiàn),腸道微生態(tài)失平衡與IBS關(guān)系密切,IBS患者腸道微生物定植抗力受損(B/E值降低),腸道微生物總體的多樣性和穩(wěn)定性普遍降低,大腸桿菌和腸球菌屬數(shù)量增加,雙歧桿菌和乳酸桿菌數(shù)量減少。IBS無(wú)特異性的治療方法,調(diào)節(jié)腸道微生態(tài)是治療IBS的重要靶點(diǎn)。益生菌可作為IBS治療的輔助手段,能否作為主要治療藥物加以推薦尚需更充分的臨床證據(jù),確切療效尚需要開(kāi)展高質(zhì)量的臨床雙盲、隨機(jī)、對(duì)照研究進(jìn)一步驗(yàn)證,尚無(wú)證據(jù)表明益生元、合生元、糞菌移植(FMT)可用于治療IBS。利福昔明治療IBS可能有效,但需要更多的證據(jù)。
[Abstract]:Irritable bowel syndrome (IBS) is a common cause of chronic abdominal pain in children. There was a close relationship between intestinal microecological imbalance and IBS. The B / E value of intestinal microbial colonization resistance was decreased, the total diversity and stability of intestinal microorganism was decreased, and the number of Escherichia coli and Enterococcus increased. The number of Bifidobacterium and Lactobacillus is reduced. There is no specific treatment for IBS. Regulation of intestinal microecology is an important target for the treatment of IBS. Probiotics can be used as an auxiliary method for IBS treatment. Whether they can be recommended as the main therapeutic drugs still needs more sufficient clinical evidence. The exact effect of probiotics still needs to carry out high quality clinical double blind, randomized, and further verified by controlled study. There is no evidence that probiotics, congeners and faecal bacteria can be used in the treatment of IBS. Rifaximin may be effective in the treatment of IBS, but more evidence is needed.
【作者單位】： 浙江大學(xué)醫(yī)學(xué)院附屬兒童醫(yī)院;
【分類號(hào)】：R725.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 Kang Nyeong Lee;Oh Young Lee;;Intestinal microbiota in pathophysiology and management of irritable bowel syndrome[J];World Journal of Gastroenterology;2014年27期

2 ;Intestinal microecology and quality of life in irritable bowe syndrome patients[J];World Journal of Gastroenterology;2004年12期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 楊瑤;李擎天;;消化道微生物組與抑郁癥[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2017年06期

2 劉煉;劉春強(qiáng);;腸道菌群與功能性便秘的研究進(jìn)展[J];遼寧中醫(yī)雜志;2017年03期

3 黃金龍;劉思敏;羅賢宇;梁文豪;邢德剛;;腸易激綜合征患者腸道目標(biāo)菌群分析[J];中國(guó)老年學(xué)雜志;2017年05期

4 陸佳;方秀才;;乳桿菌屬治療腸易激綜合征的機(jī)制[J];胃腸病學(xué)和肝病學(xué)雜志;2017年02期

5 傅麗霞;;雙歧桿菌四聯(lián)活菌片治療腹瀉型腸易激綜合征患者的療效及對(duì)血清腦腸肽水平的影響[J];中國(guó)微生態(tài)學(xué)雜志;2017年02期

6 薛愛(ài)娟;黃瑛;;益生菌在兒童炎癥性腸病的應(yīng)用[J];中國(guó)實(shí)用兒科雜志;2017年02期

7 陳潔;;調(diào)節(jié)腸道微生態(tài)治療腸易激綜合征[J];中國(guó)實(shí)用兒科雜志;2017年02期

8 Amélie Cayzeele-Decherf;Fanny Pélerin;Sébastien Leuillet;Benoit Douillard;Béatrice Housez;Murielle Cazaubiel;Gunnard K Jacobson;Peter Jüsten;Pierre Desreumaux;;Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis[J];World Journal of Gastroenterology;2017年02期

9 畢紫娟;張仕晟;袁建業(yè);;益生菌與腸易激綜合征[J];醫(yī)學(xué)綜述;2017年01期

10 鄭偉萍;何劍斌;李林;龍淼;李鵬;張q，

本文編號(hào)：1965015